ArticleEuropean journal of case reports in internal medicine2026
Spontaneous Pneumomediastinum in Rheumatoid Arthritis Associated Interstitial Lung Disease and Bronchiectasis: A Three-Component Pathophysiologic Framework.
Article in European journal of case reports in internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spontaneous pneumomediastinum is a recognized complication of connective tissue disease associated interstitial lung disease, most extensively described in dermatomyositis. Despite rheumatoid arthritis being the most common connective tissue disease with pulmonary involvement, spontaneous pneumomediastinum in rheumatoid arthritis associated lung disease has been reported only once previously. Rheumatoid arthritis uniquely causes two distinct forms of structural lung injury (interstitial lung disease and bronchiectasis) both linked to seropositive autoimmunity. An 83-year-old woman, a never-smoker with seropositive rheumatoid arthritis, progressive pulmonary fibrosis, left lower lobe bronchiectasis, low body mass index, and iatrogenic lymphopenia developed extensive pneumomediastinum during community-acquired pneumonia. Computed tomography scan demonstrated pneumomediastinum with subcutaneous emphysema, emphysematous lungs with diffuse interstitial scarring, bronchiectasis, and lobar consolidation. Conservative management with antibiotics achieved complete radiographic resolution at 8 weeks with no recurrence at 12 weeks. We hypothesize a three-component pathophysiologic framework: structural alveolar fragility from interstitial lung disease and emphysema may provide the substrate for alveolar rupture, while infection-driven coughing from true airway bronchiectasis may serve as the mechanical trigger via the Macklin effect. In rheumatoid arthritis, all three components appear driven by a shared seropositive autoimmune process. This mechanistic profile may differ fundamentally from dermatomyositis, where spontaneous pneumomediastinum is thought to reflect rapidly progressive parenchymal destruction, suggesting that dermatomyositis-derived mortality data may not be directly applicable to rheumatoid arthritis. Spontaneous pneumomediastinum in seropositive rheumatoid arthritis may follow a favourable trajectory when the mechanical trigger is reversible. High titer seropositivity, low body mass index, and iatrogenic immunosuppression may identify a convergent risk phenotype. LEARNING POINTS: Seropositive rheumatoid arthritis uniquely drives two distinct forms of structural lung injury (interstitial lung disease [ILD] and bronchiectasis) that may converge to create a substrate for spontaneous pneumomediastinum via the Macklin effect. Internists should recognize that rheumatoid arthritis (RA) patients with high-titer rheumatoid factor and anti- cyclic citrullinated peptide are at increased risk for both manifestations, and their coexistence may lower the threshold for alveolar rupture during infection-driven coughing.Not all pneumomediastinum in connective tissue diseases carries the same prognosis. When spontaneous pneumomediastinum (SPM) occurs in the setting of a reversible mechanical trigger such as acute pneumonia, conservative management with targeted antibiotics may achieve complete resolution, in contrast to the progressive-parenchymal phenotype seen in dermatomyositis, where SPM independently predicts mortality.Consider low-threshold computed tomography imaging in seropositive RA patients with known ILD and bronchiectasis who present with acute respiratory infections and chest or neck discomfort, even without the Hamman sign. Transient pneumomediastinum may be underrecognized in this population because symptoms are attributed to infection alone, and repeat imaging is not routinely performed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.